Will China Control the Global Biopharmaceutical Market?

Will China Control the Global Biopharmaceutical Market?

A legislative proposal to integrate biotechnology into the COINS Act would grant the Treasury Department new authority to scrutinize and restrict financial partnerships with Chinese entities. This regulatory pivot comes at a time when the global biopharmaceutical market is experiencing a profound transformation, moving away from traditional manufacturing toward a competition for high-end pharmaceutical innovation. A recent report from the National Security Commission on Emerging Biotechnology warns that China’s aggressive pursuit of market dominance could lead to the weaponization of medical supply chains, placing the United States’ healthcare infrastructure at a strategic disadvantage. As the People’s Republic of China transitions from a low-cost production hub to a powerhouse of drug discovery, the need for robust defensive measures has become a priority for policymakers in Washington. The challenge is to maintain a thriving research ecosystem while preventing a strategic dependency on a geopolitical rival for essential, life-saving medications.

Strategic Growth and Legislative Oversight

Can China achieve its drug discovery milestones?

China has set an ambitious goal to invent a quarter of the world’s new medications by 2030, signaling a clear shift toward “first-in-class” drug development. This roadmap is supported by a surge in licensing agreements, with over 120 deals signed between Chinese developers and Western firms since early 2025. These collaborations indicate a growing global reliance on Chinese preclinical research, suggesting that the nation is no longer just a manufacturer but a primary source of medical breakthroughs. However, this progress is often facilitated by escalating structures in deals that allow for the mass transfer of developmental expertise and regulatory know-how. Critics argue that these partnerships provide a bridge for Chinese startups to gain critical insights into Western commercialization strategies, mirroring patterns previously seen in the semiconductor and automotive sectors. As these entities absorb specialized knowledge, they are positioned to displace Western competitors by offering innovative treatments at significantly lower development costs.

The accumulation of intellectual property by foreign entities poses a significant risk to the long-term viability of the American research and development ecosystem. Analysts warn that the hollowing out of domestic innovation could occur if American firms continue to outsource the early stages of drug discovery to offshore partners. While these deals offer short-term financial gains, they often involve the surrender of proprietary data that serves as the foundation for future medical advancements. This trend is particularly evident in the field of advanced biologics, where the technical expertise required for production is being rapidly acquired by international rivals through joint ventures and state-backed investment. If this trajectory continues, the United States may find itself in a position where it must license back technologies that were originally conceived or funded within its own borders. To prevent this, industry experts suggest a reevaluation of how intellectual property is shared in international collaborations, emphasizing the need to protect the technical advantages that have defined American biotechnology.

How can the U.S. protect its biotech sector?

To counter these rising threats, the National Security Commission advocates for a legislative framework similar to the 2022 CHIPS Act to safeguard American biotechnology and maintain technological superiority. One primary recommendation involves the integration of the biotech sector into the COINS Act, which would grant the Treasury Department the authority to restrict financial transactions and partnerships with specific foreign entities. This move is designed to limit the flow of capital and sensitive data that could be used to undermine domestic interests. By creating a more rigorous screening process for international deals, the government aims to ensure that critical research and development remains under domestic control. These defensive measures are not just about economic protectionism but are focused on maintaining the integrity of the nation’s scientific infrastructure. Proponents argue that without such oversight, the United States risks losing its lead in the next frontier of global competition, where biotechnology plays a role as central as semiconductors.

Beyond legislation, the United States successfully implemented a multifaceted strategy to accelerate domestic development and streamline regulatory hurdles that previously hindered rapid innovation. Industry groups like the Biotechnology Innovation Organization (BIO) collaborated with the government to provide robust incentives for local manufacturing and research, ensuring that the next generation of treatments remained anchored within the country. These efforts included the establishment of specialized biotech zones and the expansion of tax credits for companies that prioritized domestic production. The completion of this strategic shift allowed the nation to reduce its reliance on foreign supply chains, thereby protecting patient safety during periods of global instability. By out-innovating its competitors and fostering a secure environment for scientific exploration, the federal government ensured that healthcare autonomy was maintained. These actions ultimately solidified the nation’s position as a leader in medical science, providing a secure foundation for the future of public health and national security.

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later